Klinische Monatsblatter fur Augenheilkunde · 2010
[Collagen cross-linking with riboflavin and UVA light].
Аннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hoyer A, Spörl E, Pillunat L E
Аннотация
PURPOSE: Since 1998 collagen cross-linking is used for patients with progressive keratoconus. Today it can almost be considered as the standard therapy.
METHODS: Patients with progressive keratoconus and minimal corneal thickness of 400 µm have been cross-linked within a study - (EK 310 499) approved by the ethical committee since 1998. An increase of the maximum K-value by ≥ 1 D within the last year, patient's statement of deteriorating visual acuity or the necessity of new contact len fitting more than once in 2 years were considered as progression.
RESULTS: The analysis includes 153 eyes of 111 patients with a minimal follow-up of 12 months and a maximum follow-up of 6 years. The keratectasia significantly decreased in the 1 (st) year by 2.28 D. The visual acuity improved significantly by at least one line or, respectively, remained stable (i. e., no line loss) in the 1st year in 73 %. The results remained stable over the next two years. Despite the low number of patients with a follow-up longer than 3 years and therefore limited statistical statement power, our results still indicate a long-term stabilisation or, respectively, improvement after collagen cross-linking. We saw no severe side-effects. Three patients with an exacerbated neurodermitis showed continuous progression of keratoconus and were cross-linked again.
CONCLUSIONS: To date there have been numerous promising publications on collagen cross-linking for keratoconus. The results of this study indicate that collagen cross-linking appears to be an effective therapeutic option for progressing keratoconus. Besides the clinical there are enormous economical and psychosocial benefits. Cross-linking is an out-patient, minimally-invasive, cost-effective treatment with minimal strain for the persons concerned.
METHODS: Patients with progressive keratoconus and minimal corneal thickness of 400 µm have been cross-linked within a study - (EK 310 499) approved by the ethical committee since 1998. An increase of the maximum K-value by ≥ 1 D within the last year, patient's statement of deteriorating visual acuity or the necessity of new contact len fitting more than once in 2 years were considered as progression.
RESULTS: The analysis includes 153 eyes of 111 patients with a minimal follow-up of 12 months and a maximum follow-up of 6 years. The keratectasia significantly decreased in the 1 (st) year by 2.28 D. The visual acuity improved significantly by at least one line or, respectively, remained stable (i. e., no line loss) in the 1st year in 73 %. The results remained stable over the next two years. Despite the low number of patients with a follow-up longer than 3 years and therefore limited statistical statement power, our results still indicate a long-term stabilisation or, respectively, improvement after collagen cross-linking. We saw no severe side-effects. Three patients with an exacerbated neurodermitis showed continuous progression of keratoconus and were cross-linked again.
CONCLUSIONS: To date there have been numerous promising publications on collagen cross-linking for keratoconus. The results of this study indicate that collagen cross-linking appears to be an effective therapeutic option for progressing keratoconus. Besides the clinical there are enormous economical and psychosocial benefits. Cross-linking is an out-patient, minimally-invasive, cost-effective treatment with minimal strain for the persons concerned.